Foghorn Therapeutics (FHTX) Competitors $4.87 +0.16 (+3.40%) Closing price 08/12/2025 04:00 PM EasternExtended Trading$4.97 +0.11 (+2.16%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FHTX vs. PRAX, AVDL, PAHC, PHVS, ARDX, GPCR, AMPH, VERV, SYRE, and AKBAShould you be buying Foghorn Therapeutics stock or one of its competitors? The main competitors of Foghorn Therapeutics include Praxis Precision Medicines (PRAX), Avadel Pharmaceuticals (AVDL), Phibro Animal Health (PAHC), Pharvaris (PHVS), Ardelyx (ARDX), Structure Therapeutics (GPCR), Amphastar Pharmaceuticals (AMPH), Verve Therapeutics (VERV), Spyre Therapeutics (SYRE), and Akebia Therapeutics (AKBA). These companies are all part of the "pharmaceutical products" industry. Foghorn Therapeutics vs. Its Competitors Praxis Precision Medicines Avadel Pharmaceuticals Phibro Animal Health Pharvaris Ardelyx Structure Therapeutics Amphastar Pharmaceuticals Verve Therapeutics Spyre Therapeutics Akebia Therapeutics Foghorn Therapeutics (NASDAQ:FHTX) and Praxis Precision Medicines (NASDAQ:PRAX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership. Is FHTX or PRAX more profitable? Foghorn Therapeutics has a net margin of -311.90% compared to Praxis Precision Medicines' net margin of -2,137.48%. Foghorn Therapeutics' return on equity of 0.00% beat Praxis Precision Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Foghorn Therapeutics-311.90% N/A -28.00% Praxis Precision Medicines -2,137.48%-60.07%-54.84% Do institutionals & insiders have more ownership in FHTX or PRAX? 61.6% of Foghorn Therapeutics shares are held by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are held by institutional investors. 7.6% of Foghorn Therapeutics shares are held by company insiders. Comparatively, 2.7% of Praxis Precision Medicines shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more risk & volatility, FHTX or PRAX? Foghorn Therapeutics has a beta of 3.05, suggesting that its share price is 205% more volatile than the S&P 500. Comparatively, Praxis Precision Medicines has a beta of 2.62, suggesting that its share price is 162% more volatile than the S&P 500. Which has higher earnings and valuation, FHTX or PRAX? Foghorn Therapeutics has higher revenue and earnings than Praxis Precision Medicines. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFoghorn Therapeutics$22.60M12.18-$86.62M-$1.19-4.09Praxis Precision Medicines$8.55M119.31-$182.82M-$12.29-3.94 Do analysts prefer FHTX or PRAX? Foghorn Therapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 146.41%. Praxis Precision Medicines has a consensus target price of $95.22, suggesting a potential upside of 96.50%. Given Foghorn Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Foghorn Therapeutics is more favorable than Praxis Precision Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Foghorn Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.14Praxis Precision Medicines 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.78 Does the media prefer FHTX or PRAX? In the previous week, Praxis Precision Medicines had 12 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 29 mentions for Praxis Precision Medicines and 17 mentions for Foghorn Therapeutics. Foghorn Therapeutics' average media sentiment score of 0.90 beat Praxis Precision Medicines' score of 0.18 indicating that Foghorn Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Foghorn Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Praxis Precision Medicines 4 Very Positive mention(s) 5 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral SummaryFoghorn Therapeutics beats Praxis Precision Medicines on 12 of the 17 factors compared between the two stocks. Get Foghorn Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FHTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FHTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FHTX vs. The Competition Export to ExcelMetricFoghorn TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$266.26M$2.99B$5.49B$9.68BDividend YieldN/A2.29%4.64%4.14%P/E Ratio-4.0919.9630.3825.31Price / Sales12.18353.94451.99102.74Price / CashN/A40.7837.7258.50Price / Book-3.587.658.306.01Net Income-$86.62M-$54.75M$3.26B$265.10M7 Day Performance-0.61%0.95%1.54%1.39%1 Month Performance-9.81%8.12%3.74%2.43%1 Year Performance-17.60%10.97%40.92%24.74% Foghorn Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FHTXFoghorn Therapeutics3.2592 of 5 stars$4.87+3.4%$12.00+146.4%-12.6%$266.26M$22.60M-4.09120PRAXPraxis Precision Medicines1.7678 of 5 stars$51.09-5.5%$94.11+84.2%-6.5%$1.10B$8.55M-4.77110Analyst RevisionHigh Trading VolumeAVDLAvadel Pharmaceuticals2.5839 of 5 stars$11.26+1.6%$18.33+62.8%-16.3%$1.07B$169.12M-41.7070Positive NewsEarnings ReportAnalyst RevisionPAHCPhibro Animal Health4.1862 of 5 stars$27.14+3.9%$24.40-10.1%+71.7%$1.06B$1.02B34.801,940PHVSPharvaris1.8442 of 5 stars$21.24+6.2%$36.20+70.4%+34.1%$1.05BN/A-7.0630News CoverageARDXArdelyx4.2984 of 5 stars$4.39+1.4%$10.88+147.7%-3.8%$1.04B$333.61M-19.9590Options VolumeGPCRStructure Therapeutics1.81 of 5 stars$16.78-4.6%$76.17+353.9%-43.5%$1.01BN/A-19.29136Trending NewsEarnings ReportAnalyst RevisionAMPHAmphastar Pharmaceuticals3.3985 of 5 stars$21.40+0.9%$32.33+51.1%-29.8%$999.82M$731.97M7.752,028Trending NewsAnalyst UpgradeGap UpVERVVerve Therapeutics2.9013 of 5 stars$11.13flat$14.57+30.9%N/A$992.13M$32.33M-5.27110Upcoming EarningsSYRESpyre Therapeutics2.3984 of 5 stars$16.16-0.6%$53.40+230.4%-34.6%$980.08M$890K-4.2973Positive NewsAKBAAkebia Therapeutics4.0126 of 5 stars$3.76+1.1%$6.75+79.5%+169.9%$977.01M$160.18M-17.90430 Related Companies and Tools Related Companies Praxis Precision Medicines Competitors Avadel Pharmaceuticals Competitors Phibro Animal Health Competitors Pharvaris Competitors Ardelyx Competitors Structure Therapeutics Competitors Amphastar Pharmaceuticals Competitors Verve Therapeutics Competitors Spyre Therapeutics Competitors Akebia Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FHTX) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Foghorn Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Foghorn Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access